Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > IMMUNOSTIMULATORY EFFECT OF THALIDOMIDE IN NORMAL C57BL/6 MICE IS COMPATIBLE WITH STIMULATION OF A HIGHLY CONNECTED CENTRAL IMMUNE-SYSTEM .1.
Publication

Publications

IMMUNOSTIMULATORY EFFECT OF THALIDOMIDE IN NORMAL C57BL/6 MICE IS COMPATIBLE WITH STIMULATION OF A HIGHLY CONNECTED CENTRAL IMMUNE-SYSTEM .1.

Title
IMMUNOSTIMULATORY EFFECT OF THALIDOMIDE IN NORMAL C57BL/6 MICE IS COMPATIBLE WITH STIMULATION OF A HIGHLY CONNECTED CENTRAL IMMUNE-SYSTEM .1.
Type
Article in International Scientific Journal
Year
1994
Authors
ARALACHAVES, M
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
VILANOVA, M
(Author)
ICBAS
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
RIBEIRO, A
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
PINTO, J
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Journal
Vol. 40 No. 5
Pages: 535-542
ISSN: 0300-9475
Publisher: Wiley-Blackwell
Scientific classification
FOS: Medical and Health sciences > Basic medicine
Other information
Authenticus ID: P-001-JE6
Abstract (EN): Although thalidomide has been used with success in the treatment of increasing numbers of autoimmune diseases, the therapeutic effects have not been satisfactorily explained so far. We describe here some findings that may contribute to a better understanding of the immunomodulatory effects of this drug. Several immunological changes were observed after treating C57BL/6 mice with 3 mg of thalidomide. The numbers of natural IgM PFC against sheep red blood cells were increased in the spleen, and occasionally a dramatic oscillatory increase in the numbers of non-specific splenic IgM and IgG PFC was observed in these mice. However, these oscillatory increases were progressively lower, after two and three treatments with thalidomide at 20-day intervals. Furthermore, the absolute numbers of splenic CD5(+) B and CD5(-) B lymphocytes were increased whereas depletion of CD4(+) CD8(+) cells in the thymus and of lymphoid cells in the bone marrow was seen after a single treatment with 3 mg of thalidomide. Taken together, these results suggest that thalidomide stimulates both peripheral and central immune systems and consequently enhances the connectivity of the central immune system.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 8
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

THE EFFECTS OF THALIDOMIDE TREATMENT ON AUTOIMMUNE-PRONE NZB AND MRL MICE ARE CONSISTENT WITH STIMULATION OF THE CENTRAL IMMUNE-SYSTEM .2. (1994)
Article in International Scientific Journal
VILANOVA, M; RIBEIRO, A; CARNEIRO, J; ARALACHAVES, M
SEMI-PURIFICATION OF AN IMMUNOSUPPRESSOR SUBSTANCE SECRETED BY STREPTOCOCCUS-MUTANS THAT PLAYS A ROLE IN THE PROTECTION OF THE BACTERIA IN THE HOST (1987)
Article in International Scientific Journal
SANTAREM, MMG; PORTO, MT; Paula Ferreira; SOARES, R; ARALACHAVES, MP
Role of monocytes in the up-regulation of the early activation marker CD69 on B and T murine lymphocytes induced by microbial mitogens (1996)
Article in International Scientific Journal
Vilanova, M; Tavares, D; Ferreira, P; Oliveira, L; Nobrega, A; Appelberg, R; AralaChaves, M
OPPOSING EFFECTS OF INTERLEUKIN-10 ON MOUSE MACROPHAGE FUNCTIONS (1995)
Article in International Scientific Journal
APPELBERG, R

See all (11)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-24 at 08:54:14 | Privacy Policy | Personal Data Protection Policy | Whistleblowing